Continuing at fiscal 2007 level
This article was originally published in The Tan Sheet
Executive Summary
FDA and other federal agencies will operate under fiscal 2007 appropriation levels through Nov. 16, according to a continuing resolution passed by Congress on Sept. 27. With no fiscal 2008 appropriations approved by either chamber of Congress as the end of the federal fiscal year approached, House Appropriations Committee Chairman David Obey, D-Wis., on Sept. 25 introduced H. Res. 52 to continue funding government for six weeks. The spending directive for each federal agency would be replaced by its fiscal 2008 appropriation prior to Nov. 16 in the event Congress enacts the legislation before that date, according to H. Res. 52. Like other federal agencies not within the departments of Defense and Homeland Security, FDA's entire fiscal 2007 budget was included in a continuing resolution Congress enacted in February after failing to agree on fiscal 2008 spending levels in separate bills covering the traditional grouping of agencies (1"The Tan Sheet" Feb. 19, 2007, p. 14). House Appropriations Agriculture Subcommittee Chairwoman Rosa DeLauro, D-Conn., in March said the Bush administration's fiscal 2008 budget request for FDA did not reflect the agency's needs (2"The Tan Sheet" March 5. 2007, p. 18)...
You may also be interested in...
FDA 2007 Appropriations For Food, Drug Centers Outstrip Bush Request
FDA's Center for Drug Evaluation and Research and related activities are funded at $567.59 million for fiscal 2007 under the continuing resolution passed by Congress Feb. 14 and signed into law Feb. 15
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.